A total of 15,603 patients from 32 countries and 768 sites were enrolled between October 1, 2002, and November 14, 2003, in the CHARISMA trial. Of these ...

The CHARISMA ("Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance") trial compared the effects of a dual ...

The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study enrolled 15,603 patients with stable CAD ...

1 янв. 2009 г. · The aim of this study was to determine whether clopidogrel plus aspirin provides greater protection against major cardiovascular events than aspirin alone

5 апр. 2012 г. · Description: The goal of the trial was to evaluate antiplatelet treatment with aspirin alone compared with aspirin plus clopidogrel among high- ...

12 мар. 2006 г. · A total of 15,603 patients from 32 countries and. 768 sites were enrolled between October 1, 2002, and November 14, 2003, in the CHARISMA trial.

20 июл. 2006 г. · The CHARISMA trial (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management and Avoidance) was designed to ...

1 июн. 2010 г. · In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel. The incremental risk of bleeding was greatest in the first year and similar ...

The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke ...

Conclusion: Dual antiplatelet therapy consisting of aspirin and clopidogrel provides some benefit vs aspirin alone in patients with peripheral arterial ...